Founded in 2007, Curetis is a developer of next-level molecular diagnostic solutions. Curetis focuses on the research, development and commercialisation of dependable, timely and cost-effective products that can be used to diagnose severe infectious diseases. The diagnostic achievements and progress the company is making enable rapid, multi-parameter pathogen and antibiotic resistance marker detection. It has designed the Unyvero platform, a fast, comprehensive diagnostics system that analyses severe infectious diseases in hospitalized patients. Using an array of cartridges, infectious diseases such as pneumonia or implant/tissue infections can be easily and rapidly diagnosed. While the current standard of diagnosis can take days or even weeks, Curetis can typically diagnose in four to five hours, either in a hospital laboratory or directly at the “point of need” in the intensive care unit.